Global Cell Expansion Market

Cell counting refers to any of techniques used for counting cells or quantification of cells in the life sciences for diagnosis and treatment. Cell counting is used in monitoring cell health and proliferation rate assessing immortalization or transformation, transfection or infection, seeding cells for subsequent experiments, and preparing for cell-based assays. The main consumables and accessories used in cell counting are media, sera and reagents, assay kits, microplates, accessories and other consumables. Media, sera and reagents are used as a part of cell culture and have applications in cancer research, development of biopharmaceuticals, regenerative medicine, and other research purposes. Various products include spectrophotometers, single-mode readers, multi-mode readers, cell counters, automated cell counters, hemocytometers, manual cell counters, flow cytometers and hematology analyzers. Cell counting is majorly used in for research applications, clinical and diagnostic applications and industrial applications and the end-user include hospitals and diagnostic, research institutions, pharmaceutical and biotechnology companies and others. The cell counting market research report is one of a series of new reports from The Business Research Company that provides cell counting market statistics, including cell counting industry global market size, regional shares, competitors with a cell counting market share, detailed cell counting market segments, market trends and opportunities, and any further data you may need to thrive in the cell counting industry. This cell counting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cell counting market size grew from $9.07 billion in 2022 to $9.76 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell counting market size is expected to grow to $13.04 billion in 2027 at a CAGR of 7.5%. The growing prevalence of cancer amongst the global population is the major factor expected to drive the growth of the cell counting market. Changing lifestyle and eating habits, and non-maintaining of healthy body weight is the reason for chronic diseases and other chronic infections have the risk factors for cancer. Cancer is caused by various factors such as smoking, radiation, viruses, cancer-causing chemicals (carcinogens), obesity, hormones, chronic inflammation, and a lack of exercise. The growing population and exposure to the infection lead to chronic diseases. The need for celling counting increases as there is an increase in the prevalence of cancer. For example, according to the American Cancer Society, 1.8 million new cancer cases were diagnosed in 2020, and 606,520 cancer deaths occurred in the United States. Whereas in 2021, it has been estimated as 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the US show increasing growth in chronic diseases in the country. Therefore, the growing prevalence of cancer amongst the global population drives the growth of the cell counting market. Technological advancement is a key trend gaining popularity in the cell counting market. The key players operating in the cell counting market are focused on developing new technological solutions to strengthen their position in the market. The innovative solutions of next-generation information management focus on improving patient care. This discovery should increase the capabilities that can help improve efficiency within the hospital laboratory or network with the help of data visualization and analysis software. For instance, Bio-Rad Laboratories Inc., a US-based developer and manufacturer of specialized technological products for life science research and clinical diagnostics launched TC20 Automated Cell Counter, an advanced cell counter with innovative auto-focus technology and a sophisticated cell-counting algorithm. It offers accurate mammalian cell counting in less than 30 seconds. In March 2020, Danaher Corporation, a US-based science & technology company, acquired the Biopharma business from General Electric Company's Life Sciences division for an amount of $21.4 billion. With this acquisition, Danaher wants to solve complex challenges and improve the quality of life around the world. GE is a US-based conglomerate company whose Life Sciences division consists of process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and service. Major players in the cell counting market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Biotek Instruments, Agilent Technologies, General Electric Company, Becton Dickinson and Company, Olympus Corporation, Horiba Ltd., Logos Biosystems Inc., Corning Incorporated, Abbott, Diconex, Beckman Coulter Inc., Nexcelom Bioscience LLC, ChemoMetec A/S, Advanced Instruments, R&D Systems Inc., and Cole-Parmer Instrument Company LLC. North America was the largest region in the cell counting market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell counting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cell counting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The cell counting market includes revenues earned by entities by direct total, indirect total, direct differential, and indirect differential cell counting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cell counting market is segmented - 1) By Consumables And Accessories: Media, Sera And Reagents, Assay Kits, Microplates, Accessories, Other Consumables 2) By Product: Spectrophotometers, Single-Mode Readers, Multi-Mode Readers, Cell Counters, Automated Cell Counters, Hemocytometers, Manual Cell Counters, Flow Cytometers, Hematology Analyzers 3) By Application: Research Applications, Clinical And Diagnostic Applications, Industrial Applications 4) By End-User: Hospitals And Diagnostic, Research Institutions, Pharmaceutical And Biotechnology Companies, Other End-Users

Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuge and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The cell culture consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides cell culture consumables and equipment market statistics, including cell culture consumables and equipment industry global market size, regional shares, competitors with a cell culture consumables and equipment market share, detailed cell culture consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture consumables and equipment industry. This cell culture consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cell culture consumables and equipment market grew from $10.99 billion in 2022 to $12.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell culture consumables and equipment market is expected to grow from $17.98 billion in 2027 at a CAGR of 10.4%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. In August 2021, Amerigo Scientific, a US-based manufacturer of biomedical and life sciences products, launched #D cell cultures for research purposes. FDA regulates cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment, the FDA states that if the equipment is not labelled or mentioned as sterile, it would be removed from the good manufacturing practises of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality, along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. In July 2021, Sartorius, a Germany-based laboratory instrument manufacturer, acquired Xell AG for an undisclosed amount. The acquisition would expand Sartorius’ current media offering and other cell culture products. Xell AG is a Germany-based cell culture specialist. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. North America was the largest region in the cell culture consumables and equipment market in 2022. Western Europe was the second largest region in the global cell culture consumables and equipment market report. The regions covered in the global cell culture consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture consumables and equipment market consists of sales of flasks, tubes, dishes or cryovials, serological pipettes or centrifugation tubes, bottles, cell scrapers, strainers, coverslips, and inserts. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cell culture consumables and equipment market is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Other End Users 3) By Application: Vaccination, Toxicity testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem cell technology, Regenerative Medicine, Other End Users 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges

Cell based assays are experimental tools that are designed to study reactions taking place inside the cells. These assays are used to study a mechanism or process of cellular function.  The main product and services for cell based assays are consumables, instruments, services, and software. Consumables are products that are used up or depleted during their use. The various instruments used are microplates, microplate readers, high throughput screening systems, and liquid handling systems. Different consumables include reagents and media, cells and cell lines, probes, and labels. The several technology types of cell based assays are automated handling, flow cytometry, label-free detection, high-throughput screening, and others, and they are applied for drug discovery, basic research, ADME studies, predictive toxicology, and other purposes. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CRO) and others. The cell based assays market research report is one of a series of new reports from The Business Research Company that provides cell based assays market statistics, including cell based assays industry global market size, regional shares, competitors with a cell based assays market share, detailed cell based assays market segments, market trends and opportunities, and any further data you may need to thrive in the cell based assays industry. This cell based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cell based assays market size will grow from $22.58 billion in 2022 to $24.61 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cell based assays market size is expected to grow to $36.22 billion in 2027 at a CAGR of 10.1%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (high content analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision assays for an undisclosed amount. The acquisition will solidify Cell Carta’s position in the proteomics vertical and help it better serve the customers. Precision Assays is a US-based provider of next-generation targeted proteomics testing solutions. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, Merck, Perkinelmer, Promega, Lonza, Charles River Laboratories and Cell Signaling Technology. North America was the largest region in the cell based assays market in 2022. Western Europe was the second largest region in the global cell based assays market. The regions covered in the global cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell based assays market consists of sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cell based assays market is segmented - 1) By Product & Service: Consumables, Instruments, Services, Software  2) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Other Applications 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Other Technologies 5) By Consumables: Reagents And Media, Cells And Cell Lines, Probes And Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems

Cell therapy is a type of treatment in which active cells are injected into a patient's body to treat certain disorders.This therapy seeks to treat diseases by altering certain sets of cells. In this technique, cells that originate from the patient or a donor are modified outside the body and then injected into the patient.   The main types of products in cell therapy technologies are consumables, equipment, systems & software and is applied to different type of cells, including t-cells, stem cells, and other cells. Stem cells are special human cells that can become almost any type of cell in the human body. This can range from brain cells to muscle cells and is also used to fix damaged tissues. T-cells are white blood cells and are critical to the immune system for responding against specific foreign substances or pathogens. The processes involved in cell therapy technologies include cell processing, cell preservation, distribution, handling, process monitoring, and quality control. Cell therapy technologies are used in various sectors, including life science companies and research institutes. The cell therapy technologies market research report is one of a series of new reports from The Business Research Company that provides cell therapy technologies market statistics, including cell therapy technologies industry global market size, regional shares, competitors with a cell therapy technologies market share, detailed cell therapy technologies market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy technologies industry. This cell therapy technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cell therapy technologies market size grew from $3.53 billion in 2022 to $4.24 billion in 2023 at a compound annual growth rate (CAGR) of 20.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell therapy technologies market size is expected to grow to $7.39 billion in 2027 at a CAGR of 14.9%. Increasing investments by the government in cell-based research contributed to the growth of the global cell therapy technologies market. Governments are increasingly investing in research activities for developing therapies for diseases such as cancer, cardiovascular disease (CVD), and others. For instance, in May 2022, The California Institute for Regenerative Medicine (CIRM), a research center helping stem cell research invested more than $11 million to fund a clinical trial for a cell therapy for the treatment of throat cancer. The success of this therapy will save patients from undergoing radiotherapy and its side effects. High costs associated with cell therapy are expected to restrain the market in the forecast period. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. For example, cell therapies, especially gene-editing cell therapies such as CAR-T therapy highly expensive. The two first CAR T-cell therapies, Kymriah and Yescarta, have been given price tags of $475,000 and $373,000, respectively, in the USA, with similar pricing in Europe. Thus, the high cost of cell therapy is restraining the growth of the market. Strategic collaborations and partnerships between the industry players are gaining popularity in the cell therapy technologies market. Major companies are collaborating and partnering with other companies to develop new technologies in cell therapy areas for the treatment of a variety of diseases. For instance, in August 2020, IsoPlexis Corporation, USA-based, collaborated with Lonza, a Switzerland-based chemicals and biotechnology company, to enable the next generation of precision cell therapy manufacturing. In another instance, in July 2020, Hitachi, Ltd., a Japan-based provider of a broad range of solutions including automated cell culture technologies to pharmaceutical companies in the area of cell therapy and regenerative medicine industry, collaborated with ThinkCyte, Inc., a Japan-based biotechnology company to focus on developing artificial intelligence (AI)-driven cell analysis and sorting system. In March 2020, Danaher Corporation, a USA-based company that designs, manufactures, and markets professional, medical, industrial, and commercial products and services, acquired General Electric (GE) biopharma business for $21.4 billion. The biopharma business was a part of the GE life sciences division that offered software and equipment used in biopharmaceutical research. The acquisition is expected to expand Danahe's life sciences business. General Electric Company is an American company that operates in four industrial segments: aviation, power, renewable energy, and healthcare globally. Major players in the cell therapy technologies market are Thermo Fisher Scientific, Merck, MaxCyte, Lonza Group, Sartorius, Terumo BCT, Fresenius Medical Care AG & Co. KGaA, Avantor Inc., Miltenyi Biotec, STEMCELL Technologies Inc., Beckman Coulter, Danaher, Becton Dickinson and Company, and GE Healthcare. North America was the largest region in the cell therapy technologies market in 2022. Asia-Pacific is predicted to record the fastest growth over the forecast period. The regions covered in the cell therapy technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell therapy technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cell therapy market consists of sales of cell therapy technologies that are medicinal solutions used for developing and improving cell therapy, such as cell processing, cell banking, and point-of-care technologies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cell therapy technologies market is segmented - 1) By Product: Consumables, Equipment, Systems & Software 2) By Cell Type: T-cells, Stem Cells, Other Cells 3) By Process: Cell Processing, Cell Preservation, Distribution, and Handling, Process Monitoring and Quality Control 4) By End User: Life Science Companies, Research Institutes

Cell culture refers to the growth of human, plant, or animal cells in a lab, as well as the growth of microorganisms like bacteria and yeast. Cell cultures can be used for research, medication testing, and infection diagnosis. The cells may come from multicellular eukaryotes, established cell strains, established cell lines, or any combination of these. The main types of cell culture are primary cell culture, secondary cell culture, and cell line. Primary cell cultures are those that develop from tissue explants or specific cells extracted from the source tissue. The different media include natural and artificial ones and are used in stem cell technologies, cancer research, biopharmaceuticals, tissue engineering, regenerative medicine, and others. The cell culture market research report is one of a series of new reports from The Business Research Company that provides cell culture market statistics, including cell culture industry global market size, regional shares, competitors with a cell culture market share, detailed cell culture market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture industry. This cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cell culture market grew from $22.49 billion in 2022 to $24.94 billion in 2023 at a compound annual growth rate (CAGR) of 10.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell culture market is expected to grow from $38.18 billion in 2027 at a CAGR of 11.2%. The rise in demand for cell therapy is expected to drive the cell culture market. In cell therapy, viable cells are injected or implanted into a patient's body to cure a medicinal disease. Cell culture is a vital step in any cell-based therapy. According to the Cancer Research Institute (CRI), there are about 1,483 active cell therapies in development in 2020, compared to 1,011 in 2019. Cell culture is used in the development, manufacture, and commercialization of cell therapies and holds the potential to revolutionise the healthcare industry for the treatment of various diseases. Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market. The lack of skilled professionals is expected to hinder the cell culture market’s growth. The consequence of having unskilled workers can also be detrimental to the bottom line of a company, as even a small batch error can cost an organisation millions of dollars. The regulatory agency that issues the facility's licence requires an annual report that includes all failed batches, and if the failure rate is higher than 5%, the plant may be at risk of losing its ability to sell its drug. Furthermore, in February 2022, the U.S. Bureau of Work Statistics estimated that the pandemic cost the labour force close to 8 million skilled-labor positions. In the sectors in charge of the majority of the nation's transportation, construction, and mechanical needs, nearly half of the vacancies have been filled, but about 4 million still exist. The lack of talent is expected to adversely impact the growth of the cell and gene therapy industry, thereby restraining the growth of the cell culture market. The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity. A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions, similar to how they would in a living organism. For instance, in July 2020, Rigenerand, an Italian company engaged in the production of innovative cell-based technology products for regenerative medicine and oncology, launched a 3D bioreactor called the VITVO handheld bioreactor to offer increased usability, sizing, a closed system, and flexibility for 3D cell culture technologies. Similarly, Jellagen, a UK-based marine biotechnology company, launched JellaGel, a jellyfish collagen hydrogel, suitable for 3D cell culture and tissue engineering. Danaher, a Fortune 500 science and technology company based in the United States, paid $21.4 billion for General Electric Life Sciences' biopharma business in March 2020.As a part of Danaher, the company is to be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. GE Biopharma’s offerings included cell culture media, single-use technologies, process chromatography hardware & consumables, development instrumentation and consumables, and service. Major players in the cell culture market are Thermo Fisher Scientific Inc., Corning, Inc., Becton, Dickinson, and Company, Eppendorf AG, Merck KGAA, Lonza Group AG, Sartorius AG, Promocell GmbH, Danaher, and Sartorius. North America was the largest region in the cell culture market in 2022. The Middle East is expected to be the fastest growing region in the global cell culture market during the forecast period. The regions covered in the global cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture market includes revenues earned by entities by diagnosing infections, testing new drugs, and conducting research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global cell culture market is segmented - 1) By Type: Primary Cell Culture, Secondary Cell Culture, and Cell Line 2) By Media: Natural, Artificial 3) By Applications: Stem Cell Technologies, Cancer Research, Biopharmaceutical, Tissue Engineering & Regenerative Medicine, Other Applications

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indications include b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others, and are used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumours, lung cancer, and others. The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cellular immunotherapy market grew from $4.3 billion in 2022 to $5.03 billion in 2023 at a compound annual growth rate (CAGR) of 17.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cellular immunotherapy market is expected to grow from $8.59 billion in 2027 at a CAGR of 14.3%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. For instance, in June 2022, according to a report published by the Cancer Research Institute, a US-based nonprofit organization devoted solely to developing immunotherapy for the prevention, treatment, and eventual eradication of all cancers, in the worldwide immuno-oncology pipeline as of April 2022, there were 2,756 active cell therapy drugs, up 36% from the landscape analysis of 2021 that revealed 2,031 such agents but also a slight slowdown from the 43% growth in the previous year. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients, especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient's cells, as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast production, and quality control. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced that after two or more lines of systemic therapy, the US Food and Drug Administration (FDA) has given expedited approval for Kymriah® (tisagenlecleucel) to treat adult patients with relapsed or refractory (r/r) follicular lymphoma (FL). In addition, Acepodia, a US-based next-generation cell immuno-technology company, will begin a phase 1 clinical trial in August 2020 to evaluate ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specialising in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies advance allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specialising in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC., JW CreaGene Co. Ltd., Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., and Roche. The regions covered in the global cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply c either further along the supply chain or as part of other products. The global cellular immunotherapy market is segmented - 1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, and Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin Lymphoma, Other Primary Indications 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Other Applications

Cell therapy refers to the replacement or repair of damaged tissue and/or cells through the transplantation of human cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. It is a form of treatment wherein a patient receives live cells via injection, grafting, or implant in order to produce a therapeutic result. The main techniques used in cell therapy are stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also known as regenerative medicine, uses stem cells or their derivatives to stimulate the healing response of sick, defective, or wounded tissue. The different types of therapies include allogeneic therapies, and autologous therapies and are used in various applications such as oncology, cardiovascular disease (CVD), orthopaedics, wound healing, and others. The cell therapy market research report is one of a series of new reports from The Business Research Company that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cell therapy market grew from $10.74 billion in 2022 to $12.8 billion in 2023 at a compound annual growth rate (CAGR) of 19.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell therapy market is expected to grow from $22.33 billion in 2027 at a CAGR of 14.9%. The rising prevalence of chronic diseases aided the expansion of the cell therapy market.According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more, requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Disease Control and Prevention report in 2021, due to poor nutrition and a lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease, and 4 in 10 have two or more diseases. In December 2021, according to the International Diabetes Federation, a Belgium based health organization, about 537 million people (20–79 years old) will have diabetes. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. Nearly one-half of all diabetics (240 million) go undiagnosed, and three out of every four diabetic adults live in low- and middle-income countries. According to the Parkinson’s Foundation, in 2021, approximately 60,000 Americans will be diagnosed with PD each year, and 10 million individuals worldwide will suffer from this disease. After Alzheimer's, it is the second most prevalent neurological disease. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market. The high cost of cell therapy has hindered the growth of the cell therapy market. Cell therapies have become a common choice of treatment in recent years as people look for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost around $1,000, and more specialised procedures can cost up to $100,000 depending on the condition.In the United States, the average cost of stem cell therapy in 2020 is expected to range between $4,000 and $8,000 per patient.Therefore, the high cost of cell therapy restrains the growth of the cell therapy market. Key market players are strategically partnering and collaborating to expand the company's product portfolio and geographical presence. For instance, in October 2021, Takeda, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics, a US-based company that offers cell therapies, to speed up the development of allogeneic T cell therapies for solid tumours. Furthermore, in November 2020, Sanofi, a US-based pharmaceutical company, acquired Kiadis, a Netherlands-based pharmaceutical company, to boost cell therapy, which is used to develop treatments for life-threatening diseases. Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company specialising in drug development and commercialization, paid $100 million for GammaDelta Therapeutics Limited in October 2021. Through this acquisition, Takeda will acquire early-stage cell therapy programmes in addition to GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, which encompass both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited is a UK-based biotechnology company specialising in the research and development of T-cell therapy and immunotherapy for cancer treatment. Major players in the cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., KolonTissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure. North America was the largest region in the cell therapy market in 2022. The regions covered in the global cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified), or as part of other products. The global cell therapy market is segmented - 1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy 2) By Therapy Type: Allogeneic Therapies, Autologous Therapies 3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications

Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy. The main types of products in cell and gene therapies are cell therapy and gene therapy. Gene therapy is a branch of medicine that focuses on modifying the genetic material of cells to achieve a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material. The different applications include oncology, dermatology, musculoskeletal, and others and involve various sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and others. The cell and gene therapy market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy market statistics, including global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cell and gene therapy market grew from $8.57 billion in 2022 to $10.95 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell and gene therapy market is expected to grow from $26.21 billion in 2027 at a CAGR of 24.4%. Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market. After recognising the potential of the CGT market, 16 out of the 20 largest biopharmaceutical companies by revenue, added CGT products to their portfolios. For instance, Merck invested $109 million in viral vector and gene therapy manufacturing in April 2020. Moreover, 12% of industrial clinical pipeline products and at least 16% of preclinical pipeline products consist of CGT. Steady investment and consolidation in CGT production capacity led to an increase in production capacity and also contributed to the growth of the market. Limited reimbursements preventing patients from receiving treatments are expected to limit the growth of the cell and gene therapy market., Trinity Life Sciences, a life sciences solution provider, researched national and large regional commercial health insurance plans in the US and found that the confluence of increasing price, patient volume, and number of CGTs on the market is likely to change the reimbursement model for CGTs and impact payer budgets by 5-10%. Payers realise that financing needs to be generated for cost management due to the uncertainty surrounding reimbursement of ancillary costs. Limited reimbursements and uncertain insurance plans are preventing patients from receiving high-cost CGT, which is expected to limit the market growth. Chimeric antigen receptor (CAR) T-cell therapy is shaping the cell and gene therapy (CGT) market. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient’s blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells have special structures (receptors) and are reinfused into the patient. Then, the modified receptors of T cells help in targeting the surface antigen of the cancer cell, ultimately resulting in the killing of tumour cells in patients. In 2020, the US-FDA approved Bristol-Myers Squibb's two CAR-T cell therapies to treat lymphoma and multiple myeloma and is set to be launched. Currently, FDA-approved CAR-T cells therapy treatments like Tisagenlecleucel for the treatment of B-cell precursor acute lymphoblastic leukaemia (ALL) in children and Axicabtageneciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, GT005, an experimental, one-time gene therapy now in Phase 2 for the treatment of persons with geographic atrophy (GA), will be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of gene therapies for the treatment of eye related diseases. Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio, and Fibrocell Science. North America was the largest region in the cell and gene therapys market in 2022. The regions covered in the global cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale, either further along the supply chain or as part of other products. The global cell and gene therapy market is segmented - 1) By Product: Cell Therapy, Gene Therapy 2) By Application: Oncology, Dermatology, Musculoskeletal, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users